MWC
TXMD icon

MBM Wealth Consultants’s TherapeuticsMD TXMD Stock Holding History

MBM Wealth Consultants’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-491
Closed -$5K – 282
2022
Q2 		$5K Sell
491
-106
-18% -$1.01K ﹤0.01% 240
2022
Q1 		$11K Hold
597
– – ﹤0.01% 241
2021
Q4 		$11K Hold
597
– – ﹤0.01% 229
2021
Q3 		$22K Hold
597
– – 0.01% 202
2021
Q2 		$36K Hold
597
– – 0.02% 154
2021
Q1 		$40K Hold
597
– – 0.02% 148
2020
Q4 		$36K Hold
597
– – 0.02% 147
2020
Q3 		$47K Hold
597
– – 0.03% 132
2020
Q2 		$37K Hold
597
– – 0.03% 137
2020
Q1 		$32K Buy
+597
New +$59.2K 0.03% 122

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

MBM Wealth Consultants's TXMD Position: Q3 2022 in Review

MBM Wealth Consultants sold out of TherapeuticsMD (TXMD) in Q3 2022, closing a stake of 491 shares — an estimated $5K sold.

MBM Wealth Consultants first reported a position in TXMD in Q1 2020 and held it in 10 quarters. The position peaked at $47K in Q3 2020. 43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

  • MBM Wealth Consultants reported no remaining TherapeuticsMD position as of Q3 2022 after selling out during the quarter.
  • MBM Wealth Consultants sold 491 TherapeuticsMD shares in Q3 2022, an estimated $5K.
  • MBM Wealth Consultants first reported a position in TherapeuticsMD in Q1 2020 and held it in 10 quarters.
  • MBM Wealth Consultants's TherapeuticsMD position peaked at $47K in Q3 2020.
  • 43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on MBM Wealth Consultants's 13F filing for Q3 2022, filed 24 Oct 2022.